CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M

CV Sciences, Inc.

Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.
Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.
Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.
Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.
New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CV Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $3.2 million.

Period: the quarter ended March 31, 2026
Revenue: $3.2 million
Result: reported results

Exact text from the filing

Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025

View on SEC.gov

Browse all earnings releases →

CV Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-223967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.